SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-20-008772
Filing Date
2020-10-05
Accepted
2020-10-05 17:25:31
Documents
15
Period of Report
2020-10-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_100520.htm   iXBRL 8-K 30010
2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ex23-1.htm EX-23.1 3691
3 FINANCIAL STATEMENTS FROM THE COMPANY'S ANNUAL REPORT ON FORM 10-K ex99-1.htm EX-99.1 546562
4 MANAGEMENT'S DISCUSSION AND ANALYSIS ex99-2.htm EX-99.2 83364
  Complete submission text file 0001387131-20-008772.txt   939906

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20201005.xsd EX-101.SCH 3225
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20201005_lab.xml EX-101.LAB 34591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20201005_pre.xml EX-101.PRE 22736
8 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_100520_htm.xml XML 3595
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 201224577
SIC: 2834 Pharmaceutical Preparations